Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | CHKA | P35790 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5308509 | 0.97 | ACHE (0.39) | HTTLMNAKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL16183106 | 0.77 | NFE2L2 (0.48) | KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL22953081 | 0.77 | SLC22A2 (0.38) | HTTLMNAKDM4EALDH1A1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL3381181 | 0.74 | PABPC1 (0.37) | HTTLMNAKDM4EALDH1A1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL9358685 | 0.74 | HTT (0.40) | HTTLMNAKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL5325200 | 0.72 | TYR (0.37) | HTTLMNAKDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL20507847 | 0.72 | HTT (0.35) | HTTLMNAKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL1171636 | 0.70 | KDM4E (0.38) | HTTLMNAKDM4EALDH1A1SMN1; SMN2 | |
| Iodide SCHEMBL9334776 | 0.70 | KCNN2 (0.34) | CHRNA7CHKA | |
| SCHEMBL5287705 | 0.70 | TP53 (0.43) | LMNAALDH1A1SMN1; SMN2TDP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420637-B2 | Abnormal cannabidiols as agents for lowering intraocular pressure | ALLERGAN, INC. (US) | 2013-04-16 | — | — | US | disclosed |
| US-20110269715-A1 | ABNORMAL CANNABIDIOLS AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE | ALLERGAN, INC. | 2011-11-03 | — | — | US | disclosed |
| US-7968711-B2 | Isoprenyl-3-methylcyclohex-2-enyl)benzene-1,3-diol, 2-(3,5-Difluorophenyl)-5-hydroxypyridazin-3-one, 4-Bromo-2-(2,5-dichlorophenyl)-5-hydroxypyridazin-3-one; glaucoma or ocular hypertension | ALLERGAN, INC. (US) | 2011-06-28 | — | — | US | disclosed |
| US-7718830-B2 | Abnormal cannabidiols as agents for lowering intraocular pressure | ALLERGAN, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-20100010027-A1 | ABNORMAL CANNABIDIOLS AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE | ALLERGAN, INC. | 2010-01-14 | — | — | US | disclosed |
| EP-2123264-A1 | Heterocyclic derivatives as abnormal cannabidiols agents for lowering intraocular pressure | Allergan, Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| US-7618966-B2 | Abnormal Cannabidiols as agents for lowering intraocular pressure | ALLERGAN, INC. (US) | 2009-11-17 | — | — | US | disclosed |
| US-7612101-B2 | Abnormal cannabidiols as agents for lowering intraocular pressure | ALLERGAN, INC. (US) | 2009-11-03 | — | — | US | disclosed |
| EP-2010165-A2 | ABNORMAL CANNABIDIOLS AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE | Allergan, Inc. (US) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007127711-A2 | ABNORMAL CANNABIDIOLS AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE | ALLERGAN, INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| US-20070249596-A1 | ABNORMAL CANNABIDIOLS AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE | ALLERGAN, INC. | 2007-10-25 | — | — | US | disclosed |
| US-20070249731-A1 | Abnormal cannabidiols as agents for lowering intraocular pressure | ALLERGAN, INC. | 2007-10-25 | — | — | US | disclosed |
| US-20070249581-A1 | Abnormal Cannabidiols as agents for lowering intraocular pressure | ALLERGAN, INC. | 2007-10-25 | — | — | US | disclosed |
| US-20070249602-A1 | 4-(1-isopropyl-4-methyl-1,2,5,6-tetra-hydropyridin-2-yl)-5-methylbenzene- 1,3-diol; glaucoma or ocular hypertension | ALLERGAN, INC. | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249581-A1 | Abnormal Cannabidiols as agents for lowering intraocular pressure | CNR2, CNR1, PTGIR | ACHE 593/4885HTT 3240/4885LMNA 1959/4885 |
| US-20070249596-A1 | ABNORMAL CANNABIDIOLS AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE | CNR2, CNR1, PTGIR | ACHE 541/4885HTT 3128/4885LMNA 1961/4885 |
| US-20070249731-A1 | Abnormal cannabidiols as agents for lowering intraocular pressure | CNR2, CNR1, PTGIR | ACHE 593/4885HTT 3240/4885LMNA 1959/4885 |
| US-20070249602-A1 | 4-(1-isopropyl-4-methyl-1,2,5,6-tetra-hydropyridin-2-yl)-5-methylbenzene- 1,3-diol; glaucoma or ocular hypertension | PTGIR, PTGS1, PTGIS | ACHE 1125/4885HTT 2236/4885LMNA 2623/4885 |
| US-20100010027-A1 | ABNORMAL CANNABIDIOLS AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE | CNR2, CNR1, PTGIR | ACHE 593/4885HTT 3240/4885LMNA 1959/4885 |
| US-20110269715-A1 | ABNORMAL CANNABIDIOLS AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE | CNR2, CNR1, PTGIR | ACHE 541/4885HTT 3128/4885LMNA 1961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.